Jefferies raised the firm’s price target on GE HealthCare (GEHC) to $105 from $95 and keeps a Buy rating on the shares after having hosted a call with CFO Jay Saccaro and other executives. The firm, which was “encouraged” by GE HealthCare’s Q3 performance and leading indicators, sees stable to improving fundamentals and “a strong catalyst path” with consensus appearing to model very little contribution from Flyrcado or Vizamyl/Cerianna, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare price target raised to $88 from $83 at Citi
- GE HealthCare participates in a conference call with Jefferies
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Promising Growth and Innovation Drive Buy Rating for GE Healthcare Technologies
- GE HealthCare, Mayo Clinic announce GEMINI-RT research collaboration